Smaller US winter COVID wave adds pressure to Pfizer turnaround
Health experts are seeing signs of a much smaller wave of U.S. COVID-19 cases this winter than in previous years, which could put additional pressure on Pfizer to find growth from its non-COVID tre...
Pfizer (PFE) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Exploring Analyst Estimates for Pfizer (PFE) Q4 Earnings, Beyond Revenue and EPS
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Pfizer (PFE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the q...
Pfizer Q4 Earnings Preview: 5 Critical Business Issues To Consider
Ahead of next Tuesday's earnings release, Pfizer seems undervalued based on current price of $26.55 & valuation of $150bn. But is it madness to expect upside? Quite possibly it is. My DCF analysis ...
Here's How to Play Pfizer Stock Before Q4 Earnings Release
PFE's non-COVID drugs and contributions from new and newly acquired products are likely to have driven top-line growth in the fourth quarter.
Pfizer's BRAFTOVI® Combination Regimen Demonstrates Improved Response in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as E...
Depo-Provera Contraceptive Manufacturer Pfizer Target of Consumer Lawsuit, Brain Tumors Linked to Use, According to Law Firm FeganScott
PITTSBURGH, Jan. 17, 2025 (GLOBE NEWSWIRE) -- A California woman has filed a class-action lawsuit claiming pharmaceutical giants Pfizer (PFE) and Viatris (VTRS), among others, manufactured and sold...
Pfizer to further reduce stake in Haleon through share sale
Pfizer Inc (NYSE:PFE, ETR:PFE) plans to sell around 700 million shares of Haleon PLC (LSE:HLN, NYSE:HLN), representing a 7.7% stake, via a secondary offering through an accelerated book-building pr...
Pfizer appeals denial of $75 million claim in SEC case against Cohen hedge fund
Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider trading settlement involving billionaire Steven A. Cohen's former hedge...
Pfizer Inc. (PFE) 43rd Annual J.P. Morgan Healthcare Conference (Transcript)
Pfizer Inc. (NYSE:PFE ) 43rd Annual J.P. Morgan Healthcare Conference Call January 13, 2025 12:45 PM ET Company Participants Albert Bourla - Chairman & Chief Executive Officer Conference Call Parti...
Pfizer Meets Goal in Non-Muscle Invasive Bladder Cancer Study
Data from a late-stage study shows that treatment with PFE's PD-1 inhibitor when added to BCG improves outcomes in certain bladder cancer patients.
Pfizer: My Top Play In 2025 Using Dogs Of The Dow Strategy
The 'Dogs of the Dow' strategy can be applied to Pfizer in 2025 for its 6.4% dividend and a former 'Dog.'. PFE's growth recovery, historical cheap valuation, and positive investment sentiment make ...
Pfizer's Sasanlimab in Combination with BCG Improves Event-Free Survival in Patients with BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced positive topline results from its pivotal Phase 3 CREST trial evaluating sasanlimab, an investigational anti-PD-1 monoclonal antib...
Pfizer (PFE) Stock Drops Despite Market Gains: Important Facts to Note
Pfizer (PFE) reachead $26.91 at the closing of the latest trading day, reflecting a -0.83% change compared to its last close.
Should You Buy Pfizer Stock Right Now in 2025?
Pfizer (PFE 0.20%) is an interesting healthcare company with excellent prospects for cash flow growth.
Related Companies